Anteris Technologies (ASX:AVR) is a structural heart company focused on delivering clinically superior solutions that create life-changing outcomes for patients. Anteris Technologies has developed DurAVR™ THV, which is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. It’s designed to mimic the performance of a pre-disease human aortic valve. It’s also created ADAPT®, which is a patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.